Ignite Creation Date:
2024-05-06 @ 11:09 AM
Last Modification Date:
2024-10-26 @ 12:40 PM
Study NCT ID:
NCT03440736
Status:
COMPLETED
Last Update Posted:
2023-05-22
First Post:
2018-01-31
Brief Title:
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-02-28
Start Date Type:
ACTUAL
Primary Completion Date:
2021-11-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-06-03
Completion Date Type:
ACTUAL
First Submit Date:
2018-01-31
First Submit QC Date:
February 19 2018
Study First Post Date:
2018-02-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
2021-12-10
Disp First Submit QC Date:
December 10 2021
Disp First Post Date:
2021-12-15
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2023-05-18
Last Update Post Date:
2023-05-22
Last Update Post Date Type:
ACTUAL